Latest news

• FDA sets August review date for Teva's movement disorder drug

  Huntington's disease is a much smaller market than TD but that has not stopped the only approved drug for the condition - Lundbeck's Xenazine (tetrabenazine) - bring in sales of $330m

• FDA turns down Teva's Huntington's disease drug

  In a statement, Teva said that the metabolites under scrutiny by the FDA are not novel, and are also seen in patients who take tetrabenazine. ... It is estimated that because of tolerability issues only around 5% of eligible Huntington's disease patients

• Teva drug shows promise in movement disorder

  While there is no FDA-approved drug for TD, the drug from which Teva's candidate is derived - Lundbeck's Xenazine (tetrabenazine) - has been used off-label to treat symptoms but ... Tetrabenazine is approved as an orphan drug in the US to treat chorea

• Teva starts M&A push with $3.5bn Auspex buy

  It is also relatively low risk, as the non-deuterated form of tetrabenazine is already sold as Xenazine by Lundbeck as a treatment for Huntington's and achieved sales of

• Lundbeck still feeling effects from Cipralex patent loss

  Leading the upward trend was Xenazine (tetrabenazine) for the treatment of chorea associated with Huntington's disease - up 27% to 440m krone - and Onfi (clobazam) for Lennox-Gastaut syndrome which added